SCT for severe autoimmune diseases: Consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking

Bone Marrow Transplantation

Volumn 50, Issue 2, 2015, Pages 173-180

  Alexander, T ^a   Bondanza, A ^b   Muraro, P A ^c   Greco, R ^b   Saccardi, R ^d   Daikeler, T ^e   Kazmi, M ^f   Hawkey, C ^g   Simoes, B P ^h   Leblanc, K ⁱ   Fibbe, W E ^j   Moore, J ^k   Snarski, E ^l   Martin, T ^m   Hiepe, F ^a   Velardi, A ⁿ   Toubert, A ^o   Snowden, J A ^p   Farge, D ^q  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k ST VINCENT S HOSPITAL   (Australia)

^l MEDICAL UNIVERSITY OF WARSAW   (Poland)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ UNIVERSITY OF PERUGIA   (Italy)

^o INSERM   (France)

^p SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ARTICLE; AUTOIMMUNE DISEASE; CONSENSUS; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THERAPY EFFECT; AUTOIMMUNE DISEASES; BIOBANK; MEDICAL SOCIETY; ORGANIZATION; PRESERVATION; PROCEDURES; SEVERITY OF ILLNESS INDEX; STANDARDS;

AUTOIMMUNE DISEASES; BIOLOGICAL SPECIMEN BANKS; CONGRESSES AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRESERVATION, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL;

EID: 84922407300     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.251     Document Type: Article

References (60)

1. Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplantation activity in Europe 1995. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 407-419.
2. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. for the EBMT/EULAR Scleroderma Study Group. Autologous stem cell transplantation versus vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498.
3. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van LJ et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284-292.
4. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301: 1573-1579.
5. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223.
6. Mancardi GL, Sormani MP, Di GM, Vuolo L, Gualandi F, Amato MP et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012; 18: 835-842.
7. Le BK, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
8. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci 2012; 1266: 107-117.
9. Van Bekkum DW. BMT in experimental autoimmune diseases. Bone Marrow Transplant 1993; 11: 183-187.
10. Ikehara S. Stem cell transplantation for autoimmune diseases: what can we learn from experimental models? Autoimmunity 2008; 41: 563-569.
11. Szodoray P, Varoczy L, Papp G, Barath S, Nakken B, Szegedi G et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol 2012; 41: 110-115.
12. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816.
13. Thiel A, Alexander T, Schmidt CA, Przybylski GK, Kimmig S, Kohler S et al. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol 2008; 119: 22-27.
14. Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005; 52: 1555-1563.
15. de K I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 2006; 107: 1696-1702.
16. Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013; 136: 2888-2903.
17. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005; 141: 1-9.
18. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770-790.
19. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-695.
20. van Zelm MC, van der Burg M, van Dongen JJ. Homeostatic and maturationassociated proliferation in the peripheral B-cell compartment. Cell Cycle 2007; 6: 2890-2895.
21. Sottini A, Ghidini C, Zanotti C, Chiarini M, Caimi L, Lanfranchi A et al. Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clin Immunol 2010; 136: 217-227.
22. Mensen A, Ochs C, Stroux A, Wittenbecher F, Szyska M, Imberti L et al. Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. J Transl Med 2013; 11: 188.
23. Mori A, Deola S, Xumerle L, Mijatovic V, Malerba G, Monsurro V. Next generation sequencing: new tools in immunology and hematology. Blood Res 2013; 48: 242-249.
24. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010; 59: 1721-1730.
25. Newell EW. Higher Throughput Methods of Identifying T Cell Epitopes for Studying Outcomes of Altered Antigen Processing and Presentation. Front Immunol 2013; 4: 430.
26. Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol 2013; 190: 3967-3976.
27. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337-341.
28. Caillier SJ, Briggs F, Cree BA, Baranzini SE, Fernandez-Vina M, Ramsay PP et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J. Immunol. 2008; 181: 5473-5480.
29. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37: 1108-1112.
30. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
32. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
33. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
34. Greco R, Bondanza A, Vago L, Moiola L, Rossi P, Furlan R et al. Allogeneic Hematopoietic Stem Cell Transplantation for Neuromyelitis Optica. Ann Neurol 2013; 75: 447-453.
35. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-537.
36. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
37. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-2121.
38. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A et al. HLA-DRhigh/ CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 305-308.
39. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
40. Rose T, Grutzkau A, Hirseland H, Huscher D, Dahnrich C, Dzionek A et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1639-1645.
41. Alexander T, Sattler A, Templin L, Kohler S, Gross C, Meisel A et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1549-1558.
42. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
43. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.
44. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al. Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
45. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
46. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-296.
47. Dige A, Stoy S, Rasmussen TK, Kelsen J, Hvas CL, Sandahl TD et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohns Colitis 2013; 7: 248-255.
48. Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014; 63: 1578-1586.
49. Faubion WA Jr, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 2013; 108: 1891-1900.
50. Mallone R, Roep BO. Biomarkers for immune intervention trials in type 1 diabetes. Clin Immunol 2013; 149: 286-296.
51. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Krol M et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011; 46: 562-566.
52. Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148: 1-16.
53. Mallone R, Scotto M, Janicki CN, James EA, Fitzgerald-Miller L, Wagner R et al. Immunology of Diabetes Society T-Cell Workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative. Diabetes Metab Res Rev 2011; 27: 720-726.
54. James EA, Mallone R, Schloot NC, Gagnerault MC, Thorpe J, Fitzgerald-Miller L et al. Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab Res Rev 2011; 27: 727-736.
55. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-2219.
56. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008; 67: 1360-1364.
57. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97: 9203-9208.
58. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and antiinflammatory forces in autoimmune arthritis. Rheumatology. (Oxford) 2009; 48: 602-606.
59. Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van LJ et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482-488.
60. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301-2309.